SLC5A5 and neoplasm: In contrast, in the patient showing re-induction of RAI uptake following treatment with larotrectinib, her tumor was negative for TERT promoter mutations and showed high TDS with no downregulation of the apical iodide transporter (SLC5A8) and the sodium–iodide symporter (SLC5A5) gene expression (Fig. 8).